MARKET

CAPR

CAPR

Capricor
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.000
-0.010
-0.99%
After Hours: 1.040 +0.04 +4.00% 19:43 04/03 EDT
OPEN
1.250
PREV CLOSE
1.010
HIGH
1.330
LOW
0.9901
VOLUME
9.15M
TURNOVER
--
52 WEEK HIGH
8.85
52 WEEK LOW
0.8800
MARKET CAP
8.91M
P/E (TTM)
-0.4706
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average CAPR stock price target is 6.50 with a high estimate of 9.00 and a low estimate of 4.000.

EPS

CAPR News

More
  • TSLA, ET among premarket gainers
  • Seeking Alpha - Article · 1d ago
  • Capricor Initiates Compassionate Use Program for Severe COVID-19 Patients using CAP-1002, its Novel Cell Therapy
  • GlobeNewswire · 1d ago
  • Shipping begins for Aytu rapid blood test - COVID-19 updates
  • Seeking Alpha - Article · 1d ago
  • COVID-19 actions - healthcare
  • Seeking Alpha - Article · 1d ago

Industry

Biotechnology & Medical Research
-0.50%
Pharmaceuticals & Medical Research
-0.22%

Hot Stocks

Symbol
Price
%Change

About CAPR

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapeutics. The Company focuses on discovering, developing and commercializing regenerative medicine and large molecule products for the treatment of disease, with a primary focus on the treatment of cardiovascular diseases, including orphan indications. Its product candidate, CAP-1002, a cardiosphere-derived cell product, is being tested in the ALLSTAR Phase II clinical study on patients having suffered a myocardial infarction (MI), while the DYNAMIC clinical study is testing CAP-1002 in patients in the advanced-stage of heart failure. CAP-1002 is also being tested in the HOPE-Duchenne Phase I/II clinical study for use in connection with Duchenne muscular dystrophy-related cardiomyopathy. Cenderitide, a dual receptor natriuretic peptide agonist, is being tested in a Phase II clinical study. Exosomes are nano-sized, membrane-enclosed vesicles.
More

Webull offers kinds of Capricor Therapeutics Inc stock information, including NASDAQ:CAPR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CAPR stock news, and many more online research tools to help you make informed decisions.